Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 0093-7385

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 0093-7385). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

This is a drug interaction table that shows the drugs that interact with Ethanol, Diazepam, Cimetidine, and Ketoconazole in both CYP2D6 EM's and PM's. It also presents the PK fold change and 90% Cl recommendation for AuC, Cmax, and Ccmax. The last section of the table shows recommendations for the use of drugs with caution, dose adjustment, or avoiding the concomitant use of drugs in patients with hypertension, elderly, or hepatic dysfunction.*

FDA Label Image

Image 2

This document appears to be a list of drugs and their potential interactions with other drugs, as well as recommendations for how to manage those interactions. The interactions listed include drugs like ethanol, diazepam and caffeine, and the recommendations vary from avoiding concomitant use to no dose adjustment needed. The text also mentions PKFold change and 90% C recommendation, although without further context it is difficult to determine what these mean.*

FDA Label Image

Image 3

This is a table displaying recommendations for dosage adjustments for various populations with hepatic or renal impairment, age, gender, and CYP2D6 polymorphism for the analytes Enlafaxine, Venlafaxine, and Enlataxine. The fold change and recommendation for dosage adjustment is displayed for each population. There are also sections indicating no need for dosage adjustment.*

FDA Label Image

Image 4

The text includes chemical structures and a pharmaceutical drug name "venlafaxine hydrochloride". It is likely to be related to a drug composition or formulation.*

FDA Label Image

Image 5

This is a description of Venlafaxine Hydrochloride Extended-release Capsules, USP. The medication is contained in capsules and each capsule contains veridfaie hydiochorie, USP, equbalert 1o 7.5 mg venlfaxine. The dosage instructions can be found in the package insert. The medication is manufactured by Teva Pharmaceuticals and must be kept out of reach of children. The pharmaceutical company is based in Kfar Saba, 4410202. The medication is for prescription only and comes in a package of 30 capsules. There is a serialization coding area on the package.*

FDA Label Image

Image 6

This is a medication guide for Venlafaxine Hydrochloride Capsules. The medication is extended-release and is only available by prescription. The usual dosage is specified in the package insert, and each capsule contains 175mg of Venlafaxine Hydrochloride. The medication should be stored at 20-25°C and kept out of reach of children. The medication is manufactured in Parsippany, NJ, and the packaging includes a serialization coding area. It is important to note that this description was obtained through and may contain inaccuracies or missing information.*

FDA Label Image

Image 7

This appears to be a medication guide for a drug called "hydrochloride, USP equivalent to venlafaxine" produced by Teva Pharmaceuticals. The guide includes instructions to keep the medication out of reach of children along with the manufacturing information and serialization coding area. Information regarding the print medication guides is available on the Teva USA website as per the text.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.